Artivion's second quarter is one of those printings that confuses anyone who looks only at the headline. The company lost $13.5 million on a GAAP basis, a sharp reversal of the prior year's $1.3 million of net income. Read past the accounting, and a different quarter shows up: revenue rose 11% on a GAAP basis and 9% on a non-GAAP constant-currency basis to $125.8 million; adjusted EBITDA grew 7% to $26.4 million; non-GAAP net income reached $6.3 million, or $0.13 a diluted share, comfortably ahead of the $0.10 consensus. The gap between the two reads is the cost of doing two large strategic things in the same quarter - completing the Endospan acquisition and booking the contingent milestone on the AMDS U.S. FDA approval.
Those two events are the quarter's actual story. The Endospan deal closed on May 18, 2026, expanding Artivion's aortic arch portfolio with the NEXUS family of stent grafts. The FDA approved the AMDS Hybrid Prosthesis premarket application in June, triggering a $25.0 million contingent payment to Ascyrus that was paid in July. Together with the existing ARCEVO LSA platform, Artivion now has the only complete three-pronged aortic arch portfolio in the world, and NEXUS serves as the platform for three additional PMA programs in development. The company is reiterating full-year guidance of $480 million to $496 million in revenue (7% to 11% adjusted constant-currency growth) and $92 million to $99 million in adjusted EBITDA, and management has "even greater confidence" in its ability to deliver that range after the AMDS approval.
The market's read of all of this has been mixed. Artivion trades at $28.64 as of August 12, 2026 - down 33% over the trailing year, more than 40% off the $48.25 52-week high, and roughly 9% above the $19.16 52-week low. A peer ladder of large-cap medical devices, Medtronic, Boston Scientific, Teleflex, and Penumbra, places Artivion's enterprise value at roughly 3.7x trailing sales, in line with the diversified majors but at a fraction of PEN's 8.6x. The thesis has three prongs: AMDS ramps, NEXUS integrates, the integration spend compresses into adjusted EBITDA growth. The stock is priced to deliver the guidance range, not to beat it.